Skip to main content
NIH funding notice RFA-DA-24-028

Advancing Psychedelics Research for Treating Addiction (R01 Clinical Trial Not Allowed)

Closed on November 2, 2023.

Posted
May 16, 2023
Close date
November 2, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,062,308 in first-year total cost, median $531,154.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 BSW-N (M2)]2

Most frequent institutions

  1. BRIGHAM AND WOMEN'S HOSPITAL1
  2. MEDICAL COLLEGE OF WISCONSIN1
Competing awards under RFA-DA-24-028 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024A Psilocybin-Sensitive Neuroimmune Circuit Controlling Stress Behaviors1R01DA061199-01WHEELER, MICHAEL ALEXBRIGHAM AND WOMEN'S HOSPITAL, MA$553,029ZDA1
2024Investigations into 5-HT2A signaling mechanisms of psychedelic drugs for the treatment of stimulant use disorder1R01DA061433-01HALBERSTADT, ADAM L.MCCORVY, JOHN DMURNANE, KEVIN SEANMEDICAL COLLEGE OF WISCONSIN, WI$509,279ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-DA-24-028: Advancing Psychedelics Research for Treating Addiction (R01 Clinical Trial Not Allowed) | ScienceDex | ConductScience